1. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Issue 12 (27th August 2019) Authors: Wang, Lu; Voss, Erica A.; Weaver, James; Hester, Laura; Yuan, Zhong; DeFalco, Frank; Schuemie, Martijn J.; Ryan, Patrick B.; Sun, Don; Freedman, Amy; Alba, Maria; Lind, Joan; Meininger, Gary; Berlin, Jesse A.; Rosenthal, Norman Journal: Pharmacoepidemiology and drug safety Issue: Volume 28:Issue 12(2019) Page Start: 1620 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Issue 6 (16th March 2017) Authors: Desai, Mehul; Yavin, Yshai; Balis, Dainius; Sun, Don; Xie, John; Canovatchel, William; Rosenthal, Norm Journal: Diabetes, obesity & metabolism Issue: Volume 19:Issue 6(2017) Page Start: 897 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗